Personal information

Emails & domains

Verified email domains

Activities

Collapse all

Employment (3)

University of British Columbia: Vancouver, British Columbia, CA

2020 to present | Assistant Professor (Department of Medical Genetics)
Employment
Source: Self-asserted source
Laura Evgin

BC Cancer, part of Provincial Health Services Authority: Vancouver, British Columbia, CA

2020 to present | Scientist (Michael Smith Genome Sciences Centre)
Employment
Source: Self-asserted source
Laura Evgin

Mayo Clinic: Rochester, Minnesota, US

2015 to 2020 | Postdoctoral Fellow (Department of Molecular Medicine)
Employment
Source: Self-asserted source
Laura Evgin

Education and qualifications (2)

University of Ottawa: Ottawa, Ontario, CA

2009 to 2012 | Ph.D. (Biochemistry)
Qualification
Source: Self-asserted source
Laura Evgin

University of Ottawa: Ottawa, Ontario, CA

2005 to 2009 | B.Sc. (Honours Specialization in Biochemistry)
Qualification
Source: Self-asserted source
Laura Evgin

Works (30)

Minimally modified off-the-shelf allogeneic CAR T cells

Molecular Therapy: Oncology
2024-09 | Journal article
DOI: 10.1016/j.omton.2024.200851
Contributors: Pauline Loos; Laura Evgin
Source: check_circle
Crossref

Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response

Nature Communications
2024-06-27 | Journal article
DOI: 10.1038/s41467-024-49286-x
Contributors: Mason J. Webb; Thanich Sangsuwannukul; Jacob van Vloten; Laura Evgin; Benjamin Kendall; Jason Tonne; Jill Thompson; Muriel Metko; Madelyn Moore; Maria P. Chiriboga Yerovi et al.
Source: check_circle
Crossref

Direct in vivo CAR T cell engineering

Trends in Pharmacological Sciences
2024-05 | Journal article
DOI: 10.1016/j.tips.2024.03.004
Contributors: Lauralie Short; Robert A. Holt; Pieter R. Cullis; Laura Evgin
Source: check_circle
Crossref

Lessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium

Cancer Immunology Research
2023-12-01 | Journal article
DOI: 10.1158/2326-6066.CIR-23-0522
Contributors: Christopher Alvarez-Breckenridge; Kristin G. Anderson; Ana Luisa Correia; Shadmehr Demehri; Huy Q. Dinh; Karen Olivia Dixon; Gavin P. Dunn; Laura Evgin; Jeremy Goc; Zinaida Good et al.
Source: check_circle
Crossref

Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy

2023-11-20 | Preprint
DOI: 10.21203/rs.3.rs-3576281/v1
Contributors: Richard Vile; Mason Webb; Jacob van Vloten; Laura Evgin; Thanich Sangsuwannukul; Benjamin Kendall; Jason Tonne; Jill Thompson; Muriel Metko; Madelyn Moore et al.
Source: check_circle
Crossref

Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

Science Translational Medicine
2022-04-13 | Journal article
DOI: 10.1126/scitranslmed.abn2231
Contributors: Laura Evgin; Tim Kottke; Jason Tonne; Jill Thompson; Amanda L. Huff; Jacob van Vloten; Madelyn Moore; Josefine Michael; Christopher Driscoll; Jose Pulido et al.
Source: check_circle
Crossref

Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?

Cancers
2021-03 | Journal article | Author
DOI: 10.3390/cancers13051106
Contributors: Laura Evgin; Richard G. Vile
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators.

Brain : a journal of neurology
2020-11-30 | Journal article
DOI: 10.1093/brain/awaa343
PMID: 33253355
Source: Self-asserted source
Laura Evgin

Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses.

Molecular therapy : the journal of the American Society of Gene Therapy
2020-08-25 | Journal article
DOI: 10.1016/j.ymthe.2020.08.013
PMID: 32877695
Source: Self-asserted source
Laura Evgin

Oncolytic virus-derived type I interferon restricts CAR T cell therapy.

Nature communications
2020-06-24 | Journal article
DOI: 10.1038/s41467-020-17011-z
PMID: 32581235
PMC: PMC7314766
Source: Self-asserted source
Laura Evgin

Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors.

Neuro-oncology
2020-05-27 | Journal article
DOI: 10.1093/neuonc/noaa126
PMID: 32459315
Source: Self-asserted source
Laura Evgin

APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.

Nature communications
2020-02-07 | Journal article
DOI: 10.1038/s41467-020-14568-7
PMID: 32034147
PMC: PMC7005822
Source: Self-asserted source
Laura Evgin

Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9.

Molecular therapy oncolytics
2019-12-14 | Journal article
DOI: 10.1016/j.omto.2019.12.003
PMID: 31930167
PMC: PMC6951834
Source: Self-asserted source
Laura Evgin

Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.

Journal for immunotherapy of cancer
2019-07-17 | Journal article
DOI: 10.1186/s40425-019-0673-2
PMID: 31315671
PMC: PMC6637625
Source: Self-asserted source
Laura Evgin

Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.

Cancer immunology research
2019-04-02 | Journal article
DOI: 10.1158/2326-6066.cir-18-0013
PMID: 30940643
PMC: PMC7003288
Source: Self-asserted source
Laura Evgin

APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.

Molecular therapy oncolytics
2018-08-29 | Journal article
DOI: 10.1016/j.omto.2018.08.003
PMID: 30294666
PMC: PMC6169432
Source: Self-asserted source
Laura Evgin

White paper on microbial anti-cancer therapy and prevention.

Journal for immunotherapy of cancer
2018-08-06 | Journal article
DOI: 10.1186/s40425-018-0381-3
PMID: 30081947
PMC: PMC6091193
Source: Self-asserted source
Laura Evgin

Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Clinical cancer research : an official journal of the American Association for Cancer Research
2018-05-24 | Journal article
DOI: 10.1158/1078-0432.ccr-18-1089
PMID: 29798908
Source: Self-asserted source
Laura Evgin

Infectious Optimism following the 10th International Oncolytic Virus Meeting

Molecular Therapy - Oncolytics
2017-12 | Journal article
DOI: 10.1016/j.omto.2017.08.004
Part of ISSN: 2372-7705
Source: Self-asserted source
Laura Evgin

Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.

Cancer immunology research
2017-10-15 | Journal article
DOI: 10.1158/2326-6066.cir-17-0175
PMID: 29038298
PMC: PMC5858196
Source: Self-asserted source
Laura Evgin

Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.

Molecular therapy : the journal of the American Society of Gene Therapy
2017-02-22 | Journal article
DOI: 10.1016/j.ymthe.2017.01.023
PMID: 28237836
PMC: PMC5383647
Source: Self-asserted source
Laura Evgin

Immunogenicity of self tumor associated proteins is enhanced through protein truncation.

Molecular therapy oncolytics
2016-12-07 | Journal article
DOI: 10.1038/mto.2016.30
PMID: 27933315
PMC: PMC5142466
Source: Self-asserted source
Laura Evgin

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Molecular therapy oncolytics
2016-11-16 | Journal article
DOI: 10.1038/mto.2016.27
PMID: 27909702
PMC: PMC5111574
Source: Self-asserted source
Laura Evgin

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.

Gene therapy
2016-10-25 | Journal article
DOI: 10.1038/gt.2016.70
PMID: 27779616
PMC: PMC5387692
Source: Self-asserted source
Laura Evgin

Human Blood Component Vaccinia Virus Neutralization Assay

BIO-PROTOCOL
2015 | Journal article
DOI: 10.21769/bioprotoc.1674
Part of ISSN: 2331-8325
Source: Self-asserted source
Laura Evgin

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Molecular therapy : the journal of the American Society of Gene Therapy
2015-03-25 | Journal article
DOI: 10.1038/mt.2015.49
PMID: 25807289
PMC: PMC4817751
Source: Self-asserted source
Laura Evgin

Aptamer-facilitated Protection of Oncolytic Virus from Neutralizing Antibodies.

Molecular therapy. Nucleic acids
2014-06-03 | Journal article
DOI: 10.1038/mtna.2014.19
PMID: 24892725
PMC: PMC4078759
Source: Self-asserted source
Laura Evgin

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Molecular therapy : the journal of the American Society of Gene Therapy
2011-12-20 | Journal article
DOI: 10.1038/mt.2011.276
PMID: 22186794
PMC: PMC3321594
Source: Self-asserted source
Laura Evgin

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Nature
2011-08-31 | Journal article
DOI: 10.1038/nature10358
PMID: 21886163
Source: Self-asserted source
Laura Evgin

Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.

Molecular therapy : the journal of the American Society of Gene Therapy
2010-02-16 | Journal article
DOI: 10.1038/mt.2010.14
PMID: 20160706
PMC: PMC2890119
Source: Self-asserted source
Laura Evgin

Peer review (19 reviews for 6 publications/grants)

Review activity for Journal for immunotherapy of cancer. (2)
Review activity for Molecular therapy oncolytics. (10)
Review activity for Nature (2)
Review activity for Nature reviews. (1)
Review activity for Science translational medicine. (2)
Review activity for Trends in pharmacological sciences. (2)
How many people are using ORCID?